With new name, new CEO, Cascadian now rolls out a new pivotal plan for lead cancer drug
Cascadian $CASC changed its name (from Oncothyreon) and installed a new CEO in the hope of shedding the seeming curse that dogged almost every step …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
